Abstract
Most mechanisms of drugs which are used in brain tumor chemotherapy are well characterized: alkylation of DNA components (nitrosoureas), binding with tubulin protein resulting in metaphase arrest (vincristine), chromatid breaks and chromosome translocations (procarbazine), or inhibition of ribonucleotide reductase (hydroxyurea) [1]. These drugs exert their effects mainly during certain cell cycle phases of proliferating cells, particularly when DNA is synthesized. From this it can be assumed that the efficacy of these drugs depends on the fraction of proliferating cells. Thus it would be of great importance to estimate the proliferation rate of brain tumors which could guide chemotherapy in individual patients. Positron emission tomography (PET) measures quantitatively thein vivo tissue uptake of tracer substances. In tumors, the uptake appears to be altered in a characteristic way determined by biochemical properties of tumor tissue. Some aspects of brain tumor metabolism which are theoretically related to proliferation have been investigated with PET. In the following, the literature is reviewed with regard to: 1) tracer substances whose uptake has been thought to reflect tumor malignancy (11C-methionine,18F-fluoro-deoxyglucose), and 2) tracers which theoretically could reflect mechanisms specifically related to DNA synthesis (11C-putrescine, ligands for peripheral benzodiazepine receptors).
Similar content being viewed by others
References
Shapiro WR, Shapiro JR: Principles of brain tumor chemotherapy. Semin Oncol 13: 56–69, 1986
Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P, Soussaline F, Syrota A: Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-methionine. J Neuro-Oncol 3: 397–404, 1986
Ericson K, Blomqvist G, Bergström M, Eriksson L, Stone-Elander S: Application of a kinetic model on the methionine accumulation in intracranial tumors studied with positron emission tomography. Acta Radiol 28: 505–509, 1986
Wienhard K, Herholz K, Coenen HH, Rudolf J, Kling P, Stöcklin G, Heiss WD: Increased amino acid transport into brain tumors measured by PET of L-(2-18F)Fluorotyrosine. J Nucl Med 32: 1338–1346, 1991
Patlak CS, Blasberg RG, Fenstermacher JD: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3: 1–7, 1983
Roelcke U, Radii EW, von Ammon K, Hausmann O, Maguire RP, Leenders KL: Alteration of blood-brain barrier in human brain tumors: Comparison of18F-fluorodeoxyglucose,11C-methionine and82Rubidium using PET. Personal communication, 1994
Di Chiro G, DeLaPaz RL, Brooks RA: Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurol 32: 1323–1329, 1982
Di Chiro G: Positron emission tomography using [18F] fluoro-deoxyglucose in brain tumors: A powerful diagnostic and prognostic tool. Invest Radiol 22: 360–371, 1986
Tyler JL, Diksic M, Villemure JG, Evans AC, Yamamoto YL, Feindel W: Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 28: 1123–1133, 1987
Herholz K, Pietrzyk U, Voges J, Schröder R, Halber M, Treuer H, Sturm V, Heiss WD: Correlation of glucose consumption and tumor cell density in astrocytomas. J Neurosurg 79: 853–858, 1993
Higashi K, Clavo AC, Wahl RL: Does FDG uptake measure proliferative activity of human cancer cells?In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34: 414–419, 1993
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T: Intratumoral distribution of fluorine-18-fluorodeoxyglucosein vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33: 1972–1980, 1992
Gavish M, Katz Y, Bar-Ami S, Weizman R: Biochemical, physiological, and pathological aspects of the peripheral benzodiazepine receptor. J Neurochem 58: 1589–1601, 1992
Pawlikowski M, Kunert-Radek J, Stepien H: Inhibition of cell proliferation of human gliomas by benzodiazepinesin vitro. Acta Neurol Scand 77: 231–233, 1988
Black KL, Ikezaki K, Santori E, Becker DP, Vinters HV: Specific high-affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man. Cancer 65: 823–827, 1990
Junck L, Olson JM, Ciliax BJ, Koeppe RA, Watkins GL, Jewett DM, McKeever PE, Wieland DM, Kilbourn MR, Starosta-Rubinstein S, Mancini WR, Kuhl DE, Greenberg HS, Young AB: PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 26: 752–758, 1989
Pappata S, Samson Y, Cornu P, Prenant C, Crouzel C, Benavides J, Levasseur M, Leroy-Willig A, Hauw JJ, Syrota A: Binding of 11C-PK11195 in human glioblastoma: Displacement PET studies. J Cerebr Blood Flow Metabol 11 (2): S593, 1991
Jänne J, Alhonen L, Leinonen P: Polyamines: From molecular biology to clinical applications. Ann Med 23: 241–259, 1991
Tabor CW, Tabor H: Polyamines. Ann Rev Biochem 53: 749–790, 1984
Hiesiger E, Fowler JS, Wolf AP, Logan J, Brodie JD, McPherson D, MacGregor RR, Christman DR, Volkow ND, Flamm E: Serial PET studies of human cerebral malignancy with [1-11C]putrescine and [1-11C]2-deoxy-D-glucose. J Nucl Med 28: 1251–1261, 1987
Warnick RE, Pietronigro DD, McBridge DQ, Flamm ES:In vivo metabolism of radiolabeled putrescine in gliomas: Implications for positron emission tomography of brain tumors. Neurosurg 23: 464–469, 1988
Hiesiger E, Fowler JS, Logan J, Brodie JD, MacGregor RR, Christman DR, Wolf AP: Is [1-11C]putrescine useful as a brain tumor marker? J Nucl Med 33: 192–199, 1992
Ernestus RI, Röhn G, Hossmann KA, Paschen W: Polyamine metabolism in experimental brain tumors of the rat. J Neurochem 60: 417–422, 1993
Tjuvajev J, Muraki A, Ginos J, Berk J, Koutcher J, Ballon D, Beattie B, Finn R, Blasberg R: Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 34: 1152–1162, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roelcke, U. PET: Brain tumor biochemistry. J Neuro-Oncol 22, 275–279 (1994). https://doi.org/10.1007/BF01052933
Issue Date:
DOI: https://doi.org/10.1007/BF01052933